Key Points
- Pharvaris insider Anne Lesage sold 30,000 shares at an average price of $38.30, generating $1.149 million and reducing her direct ownership by 34.7% to 56,450 shares.
- PHVS shares opened at $38.86, with a market capitalization of approximately $2.54 billion, while the company recently reported a quarterly loss of $0.81 per share—worse than analysts’ expected loss of $0.75.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $59.87; several institutions also recently increased or initiated positions in the stock.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the transaction, the insider directly owned 56,450 shares in the company, valued at $2,162,035. The trade was a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Anne Lesage also recently made the following trade(s):
- On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47.
- On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The shares were sold at an average price of $35.48, for a total value of $988,898.56.
- On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The stock was sold at an average price of $35.05, for a total value of $245,244.85.
- On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The stock was sold at an average price of $35.07, for a total value of $371,742.00.
Pharvaris Stock Performance
Shares of NASDAQ PHVS opened at $38.86 on Tuesday. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -12.74 and a beta of -2.33. The business's 50-day simple moving average is $35.20 and its 200-day simple moving average is $31.49. Pharvaris N.V. has a 52 week low of $20.65 and a 52 week high of $43.25.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on PHVS shares. Royal Bank Of Canada lifted their price target on shares of Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. New Street Research set a $60.00 target price on shares of Pharvaris in a research note on Friday, August 14th. Wall Street Zen lowered shares of Pharvaris from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. HSBC upgraded shares of Pharvaris to an "overweight" rating in a report on Thursday, August 13th. Finally, Citigroup reissued a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $59.87.
Get Our Latest Stock Report on Pharvaris
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. Alyeska Investment Group L.P. boosted its position in shares of Pharvaris by 225.5% in the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company's stock valued at $14,068,000 after acquiring an additional 281,829 shares during the period. BlackRock Inc. acquired a new stake in shares of Pharvaris in the second quarter worth $26,677,000. Seven Fleet Capital Management LP increased its position in Pharvaris by 472.3% during the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company's stock worth $8,947,000 after acquiring an additional 261,355 shares during the period. PSP Research LLC bought a new position in Pharvaris during the fourth quarter worth $569,000. Finally, DV Trading LLC acquired a new position in Pharvaris during the 1st quarter valued at $4,067,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
